You are here
NDA for Actiza Has Been Accepted for Filing by the FDA
March 4, 2004
PALO ALTO, Calif., March 4 /PRNewswire-FirstCall/ -- Connetics Corporation (NASDAQ:CNCT) , a specialty pharmaceutical company focused on dermatology, today announced that it has received confirmation that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Actiza(TM), as of December 24, 2003. Actiza is an investigational new drug formulation of 1% clindamycin delivered in the Company's proprietary VersaFoam(TM) delivery system, as a potential new topical treatment for acne.
Source: Connetics Corporation
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Gadavist® Injection Use Enables Fast Assessment
Patient Access to Inhaler Use Data Could Improve Asthma Management
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels